Small molecule FLT3 tyrosine kinase inhibitors

Research output: Contribution to journalReview article

Abstract

Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential. All rights reserved -

Original languageEnglish (US)
Pages (from-to)399-416
Number of pages18
JournalFrontiers in Medicinal Chemistry
Volume3
Issue number1
StatePublished - Jan 2006

    Fingerprint

Keywords

  • AML
  • FLT3
  • Kinase inhibitor
  • Tyrosine kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Organic Chemistry

Cite this